search
Back to results

Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers

Primary Purpose

Oily Skin, Seborrhea

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
MTC896 Gel
Sponsored by
Mimetica Pty Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Oily Skin focused on measuring Oily Skin, Sebum

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • 1. Are healthy males;
  • 2. Are between 18 and 65 years of age;
  • 3. Have self-perceived oily skin confirmed by a clinical assessment;
  • 4. Have an average Sebumeter® reading of ≥ 220 µg/cm2 on the forehead;
  • 5. Have a negative urine drug screening test result;
  • 6. Have a negative HIV and hepatitis screening test result;
  • 7. Agree to use adequate contraceptive precautions (ie, use of condoms) during the conduct of the study;
  • 8. Have a body mass index (BMI) of 19 to 34 kg/m2;
  • 9. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;
  • 10. Are willing to abstain from using any facial treatment products or personal care products (moisturizer, sunscreen, hair spray, etc) on the forehead during the study;
  • 11. Are willing to avoid sun exposure and to protect the forehead with a hat/visor;
  • 12. Are fluent in the English language;
  • 13. Complete a standard Medical Screening form as well as a Medical Personal History form; and
  • 14. Read, understand, and provide a signed informed consent.

Exclusion Criteria:

  • 1. Have any visible skin disease at the application site which, in the opinion of the investigator, will interfere with the study evaluations;
  • 2. Have a history of photosensitive reactions or a history of cutaneous or systemic lupus or other disorders frequently associated with photosensitivity;
  • 3. Are not willing to refrain from using systemic/topical analgesics such as aspirin (81 mg daily aspirin will be allowed at the discretion of the PI), Aleve, Motrin, Advil, or Nuprin for 24 hours prior to and during the study (use of acetaminophen will be permitted);
  • 4. Are using systemic/topical corticosteroids in the test area for 3 weeks prior to and during the study, or systemic/ antihistamines for 24 hours prior to and during the study;
  • 5. Are using topical retinoids, products containing benzoyl peroxide, salicylic acid, or alpha-hydroxy acids for 2 weeks prior to and during the study; or systemic retinoids within 3 months prior;
  • 6. Are using any medication which, in the opinion of the investigator, will interfere with the study evaluations;
  • 7. Have seborrheic dermatitis and/or active atopic dermatitis/eczema in or around the test sites;
  • 8. Have a known allergy and/or hypersensitivity to constituents present in the study products;
  • 9. Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
  • 10. Have received treatment for any type of internal cancer within 5 years prior to study enrollment;
  • 11. Have a history of, or are currently being treated for skin cancer;
  • 12. Are currently participating in any clinical testing; and/or
  • 13. Have received any investigational treatment(s) within 4 weeks prior to study enrollment.

Sites / Locations

  • TKL Research, Inc

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Placebo Gel

Arm Description

Outcomes

Primary Outcome Measures

A 20% reduction in sebum production as measured by the Sebumeter

Secondary Outcome Measures

Assess the safety and tolerability of the product when applied daily to the forehead for 28 days

Full Information

First Posted
December 2, 2010
Last Updated
September 11, 2014
Sponsor
Mimetica Pty Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT01254162
Brief Title
Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers
Official Title
A 4-Week, Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate the Potential of Topically Applied 0.75% (w/w) MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
July 2010 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mimetica Pty Limited

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To determine the potential of topically applied 0.75% (w/w) MTC896 Gel to reduce sebum production on the forehead of healthy male volunteers.
Detailed Description
This is a single-center, randomized, double-blind, placebo-controlled proof-of-concept study of the investigational product (0.75% (w/w) MTC896 Gel) compared to a placebo control. Subjects will be randomized to 1 of 2 treatment groups, 0.75% (w/w) MTC896 Gel or Placebo. Approximately 134 subjects will be enrolled to yield 60 completed subjects in each group. One group will receive once daily topical applications of 0.75% (w/w) MTC896 Gel to the forehead for 28 consecutive days, and the other will receive placebo under the identical regimen. Enrollment will be staggered to allow monitoring of safety and tolerability. A lead cohort will include approximately 20 subjects (10 in the MTC896 Group and 10 in the Placebo Group). Application on additional subjects will not be initiated until the lead cohort has completed the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oily Skin, Seborrhea
Keywords
Oily Skin, Sebum

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
135 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo Gel
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
MTC896 Gel
Intervention Description
0.75% w/w gel applied daily for 28 days to the forehead
Primary Outcome Measure Information:
Title
A 20% reduction in sebum production as measured by the Sebumeter
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Assess the safety and tolerability of the product when applied daily to the forehead for 28 days
Time Frame
28 days

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 1. Are healthy males; 2. Are between 18 and 65 years of age; 3. Have self-perceived oily skin confirmed by a clinical assessment; 4. Have an average Sebumeter® reading of ≥ 220 µg/cm2 on the forehead; 5. Have a negative urine drug screening test result; 6. Have a negative HIV and hepatitis screening test result; 7. Agree to use adequate contraceptive precautions (ie, use of condoms) during the conduct of the study; 8. Have a body mass index (BMI) of 19 to 34 kg/m2; 9. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events; 10. Are willing to abstain from using any facial treatment products or personal care products (moisturizer, sunscreen, hair spray, etc) on the forehead during the study; 11. Are willing to avoid sun exposure and to protect the forehead with a hat/visor; 12. Are fluent in the English language; 13. Complete a standard Medical Screening form as well as a Medical Personal History form; and 14. Read, understand, and provide a signed informed consent. Exclusion Criteria: 1. Have any visible skin disease at the application site which, in the opinion of the investigator, will interfere with the study evaluations; 2. Have a history of photosensitive reactions or a history of cutaneous or systemic lupus or other disorders frequently associated with photosensitivity; 3. Are not willing to refrain from using systemic/topical analgesics such as aspirin (81 mg daily aspirin will be allowed at the discretion of the PI), Aleve, Motrin, Advil, or Nuprin for 24 hours prior to and during the study (use of acetaminophen will be permitted); 4. Are using systemic/topical corticosteroids in the test area for 3 weeks prior to and during the study, or systemic/ antihistamines for 24 hours prior to and during the study; 5. Are using topical retinoids, products containing benzoyl peroxide, salicylic acid, or alpha-hydroxy acids for 2 weeks prior to and during the study; or systemic retinoids within 3 months prior; 6. Are using any medication which, in the opinion of the investigator, will interfere with the study evaluations; 7. Have seborrheic dermatitis and/or active atopic dermatitis/eczema in or around the test sites; 8. Have a known allergy and/or hypersensitivity to constituents present in the study products; 9. Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site; 10. Have received treatment for any type of internal cancer within 5 years prior to study enrollment; 11. Have a history of, or are currently being treated for skin cancer; 12. Are currently participating in any clinical testing; and/or 13. Have received any investigational treatment(s) within 4 weeks prior to study enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathan S Dosik, MD
Organizational Affiliation
TKL Research, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
TKL Research, Inc
City
Paramus
State/Province
New Jersey
ZIP/Postal Code
07652
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers

We'll reach out to this number within 24 hrs